+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 120Years
All Genders
ID07667400

Phase III Study of Oral SX-682 and Intravenous Docetaxel in Recurrent or Metastatic Head and Neck and Advanced Prostate Cancer

Led by National Cancer Institute (NCI) · Updated on 2026-11-04

120

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the combination of a new drug called SX-682 with an approved chemotherapy drug, docetaxel DTX, for people with recurrent or metastatic head and neck cancers including squamous cell carcinoma and salivary gland carcinoma and advanced prostate cancer. These cancers often have poor survival rates when they return or spread, and current treatments have limitations due to resistance and immunosuppressive tumor environments. This study aims to find better treatment options by targeting immune cells that promote tumor growth and resistance. Participants will receive both study drugs in 3-week cycles. SX-682 is taken orally twice daily from days 1 to 11, while DTX is given by intravenous infusion on day 8 of each cycle. Treatment continues for up to 6 cycles unless disease progression, side effects, or participant choice leads to stopping earlier. The study includes a Phase I dose-escalation part to determine the best dose of SX-682 in combination with DTX, followed by a Phase II expansion to evaluate the combinations effectiveness. Throughout the study, participants will undergo screening procedures including blood tests, imaging scans, heart function tests, and possibly tumor biopsies. They will visit the clinic on days 1 and 8 of each treatment cycle for drug administration and monitoring. After treatment ends, follow-up visits occur 1 week and 1 month later, then every 3 months for 2 years, followed by phone or email check-ins twice a year until 5 years from treatment start. Researchers will assess tumor response, safety, progression-free survival, and overall survival during this time.

CONDITIONS

Brief Title

Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

Research Team

M

Michele L Reed, R.N.

C

Charalampos Floudas, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here